Table 4 Performance of the EPI test with a cut point of 20 in the pooled cohort.

From: Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies

 

EPI ≥ cut point

EPI < cut point

Total

Performance, %

(95%CI)

Biopsy positive/≥GG2

320

46

366

Sensitivity, 87.4

(83.6–90.6)

Biopsy negative/GG1

486

360

846

Specificity, 42.6

(39.2–46.0)

Total

806

406

1212

PPV, 39.7

(36.3–43.2)

    

NPV, 88.7

(85.2–91.6)

Prevalence

30.2%

Predicted negative

33.5%

  
Back to article page